Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study - 24/04/25
, Ryan C Kubat, DO r, Wesley D Kufel, PharmD s, Jae Hyoung Lee, MD t, Alexander J Lepak, MD u, Ahmi Lim, PharmD v, Justin M Ludwig, MA w, Conan Macdougall, ProfPharmD v, Anjali Majumdar, MD p, Amy J Mathers, MD x, Erin K McCreary, PharmD a, William R Miller, MD y, Marguerite L Monogue, PharmD n, W Justin Moore, PharmD z, Shannon Olson, PharmD aa, Jessica Oxer, BS ab, Jeffrey C Pearson, PharmD ac, Christine Pham, PharmD ad, Paulette Pinargote, MD ae, Christopher Polk, MD e, Michael J Satlin, MD ab, Sarah W Satola, PhD g, Sunish Shah, PharmD w, Pranita D Tamma, MD t, Truc T Tran, MD y, David van Duin, ProfMD q, Mollie VanNatta, PharmD ae, Ana Vega, PharmD d, Veena Venugopalan, PharmD ai, Michael P Veve, PharmD af, ag, Walaiporn Wangchinda, MD f, Lucy S Witt, MD g, Janet Y Wu, PharmD ah, Jason M Pogue, ProfPharmD fon behalf of the
PRECEDENT Network†
Summary |
Background |
Ceftolozane–tazobactam and ceftazidime–avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce. Pharmacokinetic and pharmacodynamic differences between the agents might affect clinical response rates. We aimed to compare the effectiveness of ceftolozane–tazobactam and ceftazidime–avibactam for treatment of invasive multidrug-resistant P aeruginosa infections.
Methods |
This multicentre, retrospective, observational study was conducted at 28 hospitals in the USA between Jan 1, 2016, and Dec 31, 2023. Eligible patients were adults (age ≥18 years old) with microbiologically confirmed multidrug-resistant P aeruginosa pneumonia or bacteraemia treated with ceftolozane–tazobactam or ceftazidime–avibactam for more than 48 h. Patients were matched (1:1) by study site, severity of illness, time to treatment initiation (≤72 h or >72 h), and infection type. The primary outcome was clinical success at day 30, which was defined as survival, resolution of signs and symptoms of infection with the intended treatment course, and the absence of recurrent infection due to P aeruginosa. Secondary outcomes included all-cause mortality and development of resistance to study drug.
Findings |
420 eligible patients were included (210 in each treatment group), of whom 350 (83%) had pneumonia and 70 (17%) had bacteraemia. Baseline demographics, comorbidities, and severity of illness indicators were similar between groups. On treatment initiation, 336 (80%) patients were in the intensive care unit, 296 (70%) were receiving mechanical ventilation, and 168 (40%) required vasopressor support. Clinical success was observed in 128 (61%) of 210 patients treated with ceftolozane–tazobactam and 109 (52%) of 210 patients treated with ceftazidime–avibactam. By conditional logistic regression analysis, the adjusted odds ratio (aOR) of success after treatment with ceftolozane–tazobactam compared with ceftazidime–avibactam was 2·07 (95% CI 1·16–3·70). For patients with pneumonia, clinical success was observed in 110 (63%) of 175 patients in the ceftolozane–tazobactam group and 89 (51%) of 175 patients in the ceftazidime–avibactam group (aOR 2·34 [95% CI 1·22–4·47]). Among patients with bacteraemia, rates of clinical success were 51% (18 of 35 patients) for patients treated with ceftolozane–tazobactam and 57% (20 of 35 patients) for those treated with ceftazidime–avibactam (0·76 [0·23–2·57]). There were no significant differences between groups in 30-day or 90-day mortality. Among patients whose baseline isolates were tested for susceptibility, resistance developed in 22% (38 of 173) of patients treated with ceftolozane–tazobactam and 23% (40 of 177) of patients treated with ceftazidime–avibactam.
Interpretation |
Treatment with ceftolozane–tazobactam resulted in higher rates of clinical success compared with ceftazidime–avibactam for invasive infections due to multidrug-resistant P aeruginosa. Differences were driven by improved response rates for patients with pneumonia who were treated with ceftolozane–tazobactam. There were no significant differences between study groups with respect to all-cause mortality; treatment-emergent resistance was common with both agents.
Funding |
Merck Sharp & Dohme.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 25 - N° 5
P. 574-584 - maggio 2025 Ritorno al numero
Articolo precedente
- Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial
- Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, Mark Bloch, Benhur Sirvan Cetin, Ener Cagri Dinleyici, Daniel Dražan, Satu Kokko, Susanna Koski, Outi Laajalahti, Joanne M Langley, Mika Rämet, Peter C Richmond, Peter Silas, Bruce Tapiero, Florence Tiong, Mary Tipton, Benita Ukkonen, Betul Ulukol, Maria Lattanzi, Mauro Trapani, Arnold Willemsen, Daniela Toneatto, QUINTET study group, Mark Bloch, Peter Richmond, Eugene Athan, Terry Nolan, Marije Dalebout, Florence Tiong, Ferdinandus de Looze, Ener Cagri Dinleyici, Tolga Ince, Benhur Cetin, Betul Ulukol, Jiří Beran, Daniel Dražan, Renata Adamovska, Martina Spaziererova, Josef Zemanek, Miroslav Pavlasek, Sandra Meisalu, Kaia Kiiroja, Mika Rämet, Ilkka Seppä, Susanna Koski, Benita Ukkonen, Satu Kokko, Outi Laajalahti, Pauliina Paavola, Marc Dionne, Anil Gupta, Joanne Langley, James Kellner, Bruce Tapiero, Noah Vale, Marie-Louise Vachon, Manish Sadarangani, Peter Dzongowski, Mary Tipton, Walter Rok, Martin Schear, William Simon, Jonathan Staben, Paul Grubb, Robert Jeanfreau, Enrique Pelayo, Minesh Patel, Rambod Rouhbakhsh, Peter Silas, Daniel Finn, Joseph Surber, George Freeman, Maia Chakerian, Alexander Osowa, Kwabena Ayesu, Jake Jones, Ryan Gottfredson, John Scott, William Byars, Hemalini Mehta, Robert Carter, Rand Farjo, Ronald Ackerman, David Bernard, Yamirka Sanchez, Maria Lattanzi, Mauro Trapani, Chiranjiwi Bhusal, Daniela Toneatto, Arnold Willemsen, Isabelle Lechevin, Stefanie Raulier, Dominique Wauters, Danielle Morelle
- Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study
- Katia Alves, Karen Kotloff, R Scott McClelland, Alex Kouassi, Joyce S Plested, Raj Kalkeri, MingZhu Zhu, Shane Cloney-Clark, Zhaohui Cai, Katherine Smith, Muneer Kaba, Joy Nelson, E Adrianne Hammershaimb, Raburn M Mallory, Fernando Noriega, 2019nCoV-313 Study Investigators, Jeffrey Adelglass, Adebayo Akinsola, Brandon Alleman, Codey Bell, Laurence Chu, Matthew Davis, Sue Fanning, David Ferrera, George Freeman, Linda Gorgos, Ripley Hollister, Michael Jacobs, Craig Julien, Karen Kotloff, Robert Lockwood, R. Scott McClelland, Jara McDonald, Abel Murillo, Robert Noveck, Paul Pickrell, William Seger, Stacy Slechta, William Smith, Harry Studdard, Ronald Surowitz, Milagritos Tapia, Eduardo Uribe, Keith Vrbicky, Larkin Wadsworth, Kem Yenal, Pedro Ylisastigui
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?